Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial

Roch Houot, Viola Poeschel, Bettina Altmann, Thomas Illmer, Marc André, Martin Dreyling, Herve Maisonneuve, Herve Tilly, Stephanie Mayer, Rene-Olivier Casasnovas, Steven Le Gouill, Fritz Offner, Guillaume Cartron, Andrea Kerkhoff, Thomas Weber, Joerg Hoffmann, Marita Ziepert, Wolfram Klapper, Emmanuel Itti, Dirk Hellwig, Laurence de Leval, Andreas Rosenwald, Corinne Haioun, Laurent Dercle, Philippe Gaulard, Gerhard Held

Open source

DOI: 10.1182/blood-2020-136941
Published: 2020-11-05
Container: Blood
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/blood-2020-136941,
  title = {Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial},
  author = {Roch Houot and Viola Poeschel and Bettina Altmann and Thomas Illmer and Marc André and Martin Dreyling and Herve Maisonneuve and Herve Tilly and Stephanie Mayer and Rene-Olivier Casasnovas and Steven Le Gouill and Fritz Offner and Guillaume Cartron and Andrea Kerkhoff and Thomas Weber and Joerg Hoffmann and Marita Ziepert and Wolfram Klapper and Emmanuel Itti and Dirk Hellwig and Laurence de Leval and Andreas Rosenwald and Corinne Haioun and Laurent Dercle and Philippe Gaulard and Gerhard Held},
  year = {2020},
  journal = {Blood},
  doi = {10.1182/blood-2020-136941},
  url = {https://doi.org/10.1182/blood-2020-136941}
}

RIS

TY  - JOUR
TI  - Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial
AU  - Roch Houot
AU  - Viola Poeschel
AU  - Bettina Altmann
AU  - Thomas Illmer
AU  - Marc André
AU  - Martin Dreyling
AU  - Herve Maisonneuve
AU  - Herve Tilly
AU  - Stephanie Mayer
AU  - Rene-Olivier Casasnovas
AU  - Steven Le Gouill
AU  - Fritz Offner
AU  - Guillaume Cartron
AU  - Andrea Kerkhoff
AU  - Thomas Weber
AU  - Joerg Hoffmann
AU  - Marita Ziepert
AU  - Wolfram Klapper
AU  - Emmanuel Itti
AU  - Dirk Hellwig
AU  - Laurence de Leval
AU  - Andreas Rosenwald
AU  - Corinne Haioun
AU  - Laurent Dercle
AU  - Philippe Gaulard
AU  - Gerhard Held
PY  - 2020
JO  - Blood
DO  - 10.1182/blood-2020-136941
UR  - https://doi.org/10.1182/blood-2020-136941
ER  -

APA

Houot, R., Poeschel, V., Altmann, B., Illmer, T., André, M., Dreyling, M., Maisonneuve, H., Tilly, H., Mayer, S., Casasnovas, R., Gouill, S. L., Offner, F., Cartron, G., Kerkhoff, A., Weber, T., Hoffmann, J., Ziepert, M., Klapper, W., Itti, E., Hellwig, D., Leval, L. D., Rosenwald, A., Haioun, C., Dercle, L., Gaulard, P., & Held, G. (2020). Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial. Blood. https://doi.org/10.1182/blood-2020-136941

Source records

hal · retrieved 2026-09-26T04:02:50.192Z